ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Bone density"

  • Abstract Number: 1886 • 2017 ACR/ARHP Annual Meeting

    Continued Fracture Risk Reduction after 12 Months of Romosozumab Followed By Denosumab through 36 Months in the Extension of the Phase 3 Fracture Study in Postmenopausal Women with Osteoporosis

    E Michael Lewiecki1, Rajani V Dinavahi2, Marise Lazaretti-Castro3, Peter R Ebeling4, J Adachi5, Akimitsu Miyauchi6, Evelien Gielen7, Cassandra E Milmont2, Cesar Libanati8 and Andreas Grauer2, 1New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, 2Amgen Inc., Thousand Oaks, CA, 3Federal University of São Paulo, São Paulo, Brazil, 4Monash University, Melbourne, Australia, 5McMaster University, Hamilton, ON, Canada, 6Miyauchi Medical Center, Osaka, Japan, 7University Hospitals Leuven, Leuven, Belgium, 8UCB Pharma, Brussels, Belgium

    Background/Purpose: Romosozumab (Romo) is a monoclonal antibody that binds sclerostin with a dual effect, increasing bone formation and decreasing bone resorption. In the primary analysis…
  • Abstract Number: 1937 • 2017 ACR/ARHP Annual Meeting

    Abaloparatide, an Osteoanabolic PTHrP Analog, Increased Bone Mineral Density in Rabbits with Glucocorticoid Induced Osteopenia

    Heidi Chandler1, Allen Pierce2, Jeffery Brown2, Michael Ominsky2 and Gary Hattersley3, 1Research, Radius Health Inc, Waltham, MA, 2Radius Health Inc, Waltham, MA, 3Radius Health, Inc., Waltham, MA

    Background/Purpose: Estrogen deficiency and glucocorticoid (GC) therapy are the main causes of postmenopausal and secondary osteoporosis, respectively. Bone loss in both states relate to a…
  • Abstract Number: 2002 • 2017 ACR/ARHP Annual Meeting

    Baseline 18F Sodium Fluoride Uptake of Vertebral Bodies but Not Vertebral Corners on Positron Emission Tomography Is Associated with Changes in Bone Mineral Density at Lumbar Vertebrae in Ankylosing Spondylitis: A 1-Year Longitudinal Study

    Seung-Geun Lee1, Keunyoung Kim2, Seong-Min Kweon3, Eun-Kyoung Park4, Yun-Kyung Kim5 and Geun-Tae Kim6, 1Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, Korea, Republic of (South), 2Department of Nuclear Medicine and Biomedical Research Institute, Pusan National University Hospital, Busan, Korea, Republic of (South), 3Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, South Korea, Busan, Korea, Republic of (South), 4Division of Rheumatology, Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea, Republic of (South), 5Internal Medicine, Kosin University College of Medicine, Busan, South Korea, Busan, Korea, Republic of (South), 6Kosin University College of Medicine, Busan, Korea, Republic of (South)

    Background/Purpose: 18F sodium fluoride (NaF) positron emission tomography (PET) allows quantitative assessment of osteoblastic bone synthesis in specific skeletal sites. Previous studies showed that increased…
  • Abstract Number: 2201 • 2017 ACR/ARHP Annual Meeting

    Baseline Periarticular Tibial Knee Bone Mineral Density Is Associated with Change in Static Alignment

    Grace H. Lo1, Jeffrey B. Driban2, Michael T. Strayhorn3, Lori Lyn Price4, Charles Eaton5 and Timothy E. McAlindon6, 1Immunology, Allergy, Rheumatology, Baylor College of Medicine, Houston, TX, 2Rheumatology, Tufts Medical Center, Boston, MA, 3VA HSR&D Center for Innovations in Quality, Effectiveness and Safety; Department of Medicine, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX, 4Tufts Clinical and Translational Science Institute, Tufts University, Boston, MA, 5Family Medicine and Epidemiology, Warren Alpert Medical School, School of Public Health, Brown University, Providence, RI, 6Division of Rheumatology, Tufts Medical Center, Boston, MA

    Background/Purpose: Relative local knee periarticular bone mineral density (paBMD) as measured by dual x-ray absorptiometry (DXA) has been associated with static alignment cross-sectionally, but not…
  • Abstract Number: 2367 • 2017 ACR/ARHP Annual Meeting

    The Effect of Glucocorticoids on Bone Mineral Density in Patients with Rheumatoid Arthritis:  a Systematic Review and Meta-Analysis

    Anne-Birgitte Blavnsfeldt1,2, Malissa Dawn Thomsen3, Simon Tarp4, Bente Langdahl2,5, Ellen-Margrethe Hauge2,6 and Annette de Thurah7,8, 1Rheumatology, Aarhus Universityhospital, Aarhus C, Denmark, 2Department of Clinical Medicine, Aarhus University, Aarhus C, Denmark, 3Diagnostic Centre, Silkeborg Regional Hospital, Silkeborg, Denmark, 4The Parker Institute, Bispebjerg & Frederiksberg Hospital, Copenhagen, Denmark, 5Endocrinology, Aarhus University Hospital, Aarhus, Denmark, 6Aarhus Universityhospital, Aarhus C, Denmark, 7Department of Rheumatology, Aarhus University Hospital, Aarhus, DK, Aarhus, Denmark, 8Department of Clinical Medicine, Aarhus University, Aarhus, Denmark

    Background/Purpose: The role of glucocorticoids (GCs) in the treatment of rheumatoid arthritis (RA) is widely debated. GCs stimulate bone resorption and impair bone formation. Inflammatory…
  • Abstract Number: 2369 • 2017 ACR/ARHP Annual Meeting

    Relationship of Bone Mineral Density and Inflammatory Burden with Carotid Plaque Formation in Rheumatoid Arthritis: A 5-Year Prospective Study

    Na Ri Kim, Jong Wan Kang, Jung Su Eun, Ji Hun Kim, Jin Young Kang, Gi Bum Bae, Sang Jin Lee, Eon Jeong Nam and Young Mo Kang, Division of Rheumatology, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea, Republic of (South)

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic and systemic inflammatory disease. The incidence of the cardiovascular (CV) disease is significantly increased in patients with RA…
  • Abstract Number: 2379 • 2017 ACR/ARHP Annual Meeting

    Effect of DKK-1 and Osteoprotegerin on Bone Mass in Tightly Controlled Rheumatoid Arthritis

    Javier Narváez1, Irene Martin-Esteve2, Andrea Zacarias3, Pedro Alia4, Estibaliz Loza5, Loreto Carmona5, Joan Miquel Nolla2 and Carmen Gomez Vaquero6, 1Rheumatology Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, 2Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 3Hospital Universitari de Bellvitge, Barcelona, Spain, 4Clinical Laboratory Service, Hospital Universitari de Bellvitge - IDIBELL, Barcelona, Spain, 5Instituto de Salud Musculoesquelética (InMusc), Madrid, Spain, 6Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain

    Background/Purpose:  To analyze the association between osteoprotegerin (OPG) and Dickkopf-related protein 1 (DKK-1) and the annual percent change (Δ%) in bone mineral density (BMD) in patients…
  • Abstract Number: 318 • 2017 ACR/ARHP Annual Meeting

    A Randomized Alendronate-Controlled Trial of Romosozumab: Results of the Phase 3 Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk

    Kenneth Saag1, Jeffrey Petersen2, Maria Luisa Brandi3, Andrew Karaplis4, Mattias Lorentzon5, Thierry Thomas6, Judy Maddox2, Michelle Fan2, Paul D. Meisner7 and Andreas Grauer2, 1University of Alabama, Birmingham, AL, 2Amgen Inc., Thousand Oaks, CA, 3University of Florence, Florence, Italy, 4McGill University, Montreal, QC, Canada, 5University of Gothenburg and Sahlgrenska University Hospital, Mölndal, Sweden, 6CHU de Saint-Étienne, Saint-Étienne, France, 7UCB Pharma, Brussels, Belgium

    Background/Purpose: The bone forming agent romosozumab (Romo) was previously shown to reduce vertebral and clinical fractures in postmenopausal women with osteoporosis. Here we report the…
  • Abstract Number: 2514 • 2017 ACR/ARHP Annual Meeting

    When Should Lateral Dexa be Used to Measure Spine Bone Mineral Density in Axial Spondyloarthritis Patients: A Cross-Sectional Study

    Sizheng Zhao1,2, Daniel Thong3, Eleanor Quilliam2, Stephen Duffield1, Kai-Wei Yin3 and Nicola Goodson1,2, 1Musculoskeletal Biology 1 Department, University of Liverpool, Liverpool, United Kingdom, 2Aintree University Hospital, Liverpool, United Kingdom, 3University of Liverpool, Liverpool, United Kingdom

    Background/Purpose: Osteoporosis and vertebral fractures are recognized complications in axial spondyloarthritis (axSpA). Anteroposterior (AP) DEXA is commonly used to assess spinal bone mineral density (BMD)…
  • Abstract Number: 324 • 2017 ACR/ARHP Annual Meeting

    The Predictors of the Efficacy of Denosumab, a Monoclonal Antibody to RANK Ligand, on Osteoporosis in Rheumatoid Arthritis Patients from Japanese Multicenter Study

    Kyosuke Hattori1, Yuji Hirano1, Yasuhide Kanayama2, Nobunori Takahashi3, Naoki Ishiguro3 and Toshihisa Kojima3, 1Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, 2Orthopaedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan, 3Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan

    Background/Purpose: Although early intensive treatment has improved medication of rheumatoid arthritis (RA), treatment for osteoporosis (OP) in RA patient will be more important. Here, we…
  • Abstract Number: 2911 • 2017 ACR/ARHP Annual Meeting

    Low Appendicular Bone Mass Predicts Mortality in Patients with Rheumatoid Arthritis

    Mark Edward Hall1, Inmaculada del Rincon2, Jose Felix Restrepo2, Daniel F. Battafarano3, Jakob Algulin4 and Agustin Escalante2, 1Internal Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, 2Internal Medicine-Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, 3Medicine, San Antonio Military Medical Center, San Antonio, TX, 4Sectra AB, Linköping, Sweden

    Background/Purpose: Rheumatoid Arthritis (RA) is a multi-system disease which causes joint damage and is associated with increased cardiovascular (CV) morbidity and osteoporosis. Our purpose is…
  • Abstract Number: 330 • 2017 ACR/ARHP Annual Meeting

    Change in Bone Mineral Density in Patients with Rheumatoid Arthritis: Minimal 10-Year Follow-up

    Hiraku Motomura, Isao Matsushita, Toshihito Hiraiwa and Tomoatsu Kimura, Department of Orthopaedic Surgery, Faculty of Medicine, University of Toyama, Toyama, Japan

    Background/Purpose: To investigate the long-term change in bone mineral density (BMD) in patients with rheumatoid arthritis (RA). Methods: In a longitudinal study of 40 patients…
  • Abstract Number: 331 • 2017 ACR/ARHP Annual Meeting

    Case Series: Comparison of Repository Corticotropin Injection (H.P. Acthar Gel) Versus Glucocorticoids on Bone Density in SLE Patients

    Anny T. Wu1 and Joshua June2, 1Rheumatology, Franciscan Alliance, Munster, IN, 23394 E Jolly Rd Ste C, Great Lakes Center of Rheumatology, Lansing, MI

    Background/Purpose: Repository Corticotropin Injection (RCI) is an adrenocorticotropin hormone in 16% gelatin with a prolonged release after intramuscular (IM) or subcutaneous injection. Adverse effects of…
  • Abstract Number: 334 • 2017 ACR/ARHP Annual Meeting

    Comparison of Outcomes in Osteoporosis in Patients on Denosumab between Standard and Non-Standard Dosing Intervals

    Nouman A. Syed, Mohammed Wiqar, Douglas Einstadter and Marina N. Magrey, Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH

    Background/Purpose: Denosumab (Dmab) is an antiresorptive agent with an approximate half-life of 26 days and according to the prescribing information the recommended dose is 60…
  • Abstract Number: 1218 • 2017 ACR/ARHP Annual Meeting

    Caffeine Consumption and Risk of Osteoporosis: A Cross Sectional Study of 3, 210 Patients from the National Health and Nutrition Examination Survey

    Nicola Berman1, Teresa Attina2, Bruce Cronstein1, Stephen Honig1 and Michael Pillinger1, 1Rheumatology, New York University School of Medicine, Division of Rheumatology, New York, NY, 2Pediatrics, New York University School of Medicine, New York, NY

    Background/Purpose: Adenosine regulates bone metabolism. In vitro studies suggest that direct stimulation of the adenosine A2A receptor increases osteoblasts and diminishes osteoclasts, and thus inhibition…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 14
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology